Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 peptide-loaded allogeneic dendritic cell vaccine + donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, Peptides, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
This therapeutic regimen is a combination of a donor-derived dendritic cell (DC) vaccine and donor lymphocyte infusion (DLI) developed by the National Cancer Institute (NCI). It is specifically designed for patients with WT1-expressing hematologic malignancies—including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and lymphomas—who have relapsed after allogeneic hematopoietic stem cell transplantation. The vaccine consists of monocyte-derived dendritic cells pulsed with three HLA-A2 binding Wilms' tumor 1 (WT1) peptides (WT1 37–45, 126–134, and 187–195) linked to an HIV TAT protein transduction domain. The goal of the vaccine is to stimulate a donor-derived, WT1-specific T-cell response, which is further augmented by the infusion of donor lymphocytes to enhance the graft-versus-leukemia (GVL) effect.
- Other names
- WT1 DC vaccine + DLIWT1 peptide-pulsed dendritic cells + donor lymphocytesWT1 peptide-loaded allogeneic dendritic cell vaccine and donor lymphocyte infusionWT-1 peptide-loaded allogeneic dendritic cell vaccine and donor lymphocyte infusionWT 1 peptide-loaded allogeneic dendritic cell vaccine and donor lymphocyte infusion
Beyond the preview
Go deeper on WT1 peptide-loaded allogeneic dendritic cell vaccine + donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 peptide-loaded allogeneic dendritic cell vaccine + donor lymphocyte infusion.